1,25-Dihydroxyvitamin D(3) Inhibits Podocyte uPAR Expression and Reduces Proteinuria

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Ma, Jianchao ^a,b   Zhang, Bin ^b   Liu, Shuangxin ^b   Xie, Shaoting ^b   Yang, Yun ^b   Ma, Juan ^b   Deng, Yujun ^b   Wang, Wenjian ^b   Xu, Lixia ^b   Li, Ruizhao ^b   Zhang, Li ^b   Yu, Chunping ^b   Shi, Wei ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; LIPOPOLYSACCHARIDE; MESSENGER RNA; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFECT; FLOW CYTOMETRY; GLOMERULOSCLEROSIS; GLOMERULUS; IMMUNOCYTOCHEMISTRY; MOUSE; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PODOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

ANIMALS; CELL MOVEMENT; DISEASE MODELS, ANIMAL; KIDNEY GLOMERULUS; MALE; MICE; PODOCYTES; PROTEINURIA; RATS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; VITAMIN D;

MUS; RATTUS;

EID: 84878614295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064912     Document Type: Article

References (40)

1. Keane WF, Eknoyan G, (1999) Proteinuria, albuminuria, risk, assessment,detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 33: 1004-1010.
2. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, et al. (2012) Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis 59: 67-74.
3. Jørgensen HS, Winther S, Povlsen JV, Ivarsen P, (2012) Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study. BMC Nephrol 13: 102.
4. Cheng J, Zhang W, Zhang X, Li X, Chen J, (2012) Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 7: 391-400.
5. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, et al. (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376: 1543-1551.
6. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, et al. (2004) 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286: F526-33.
7. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, et al. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73: 163-171.
8. Zou MS, Yu J, Zhou JH, Nie GM, Ding DS, et al. (2010) 1,25-Dihydroxyvitamin D3 ameliorates podocytopenia in rats with adriamycin-induced nephropathy. Intern Med 49: 2677-2686.
9. Zou MS, Yu J, Nie GM, He WS, Luo LM, et al. (2010) 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int J Med Sci 7: 290-299.
10. Xiao H, Shi W, Liu S, Wang W, Zhang B, et al. (2009) 1,25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am J Nephrol 30: 34-43.
11. Mundel P, Reiser J, (2010) Proteinuria: an enzymatic disease of the podocytes. Kidney Int. 77: 571-580.
12. Patrakka J, Tryggvason K, (2009) New insights into the role of podocytes in proteinuria. Nat Rev Nephrol 5: 463-468.
13. Tryggvason K, Patrakka J, Wartiovaara J, (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354: 1387-1401.
14. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, et al. (2004) Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem 279: 34827-34832.
15. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, et al. (2006) Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8: 485-491.
16. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, et al. (2008) Modification of kidney barrier function by the urokinase receptor. Nat Med 14: 55-63.
17. Zhang B, Xie S, Shi W, Yang Y, (2012) Amiloride off-target effect inhibits podocytes urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 27: 1746-1755.
18. Zhang B, Shi W, Ma J, Sloan A, Faul C, et al. (2012) The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl) 90: 1407-1420.
19. Cheng CC, Lee YF, Lan JL, Wu MJ, Hsieh TY, et al. (2013) Mycophenolate mofetil alleviates lupus nephritis through urokinase receptor signaling in a mice model. Lupus 11. [Epub ahead of print].
20. Luft FC, (2012) uPAR signaling is under par for the podocyte course. J Mol Med(Berl) 90: 1357-1359.
21. Blasi F, Carmeliet P, (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943.
22. Smith HW, Marshall CJ, (2010) Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11: 23-36.
23. Huang J, Liu G, Zhang YM, Cui Z, Wang F, et al. (2013) Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 27. doi: 10.1038/ki.2013.55.
24. Reiser J, Wei C, Tumlin J, (2012) Soluble urokinase receptor and focal segmental glomerulosclerosis. Curr Opin Nephrol Hypertens 21: 428-432.
25. Wei C, Trachtman H, Li J, Dong C, Friedman AL, et al. (2012) PodoNet and FSGS CT Study Consortia. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 23: 2051-2059.
26. Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, et al. (2013) Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther 20: 226-229.
27. Maas RJ, Deegens JK, Wetzels JF (2013) Serum suPAR in patients with FSGS: Trash or treasure? Pediatr Nephrol 21. [Epub ahead of print].
28. Wei C, Hindi SE, Li J, Fornoni A, Goes N, et al. (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis Nat Med. 17: 952-960.
29. Li YC, (2011) Podocytes as target of vitamin D. Curr Diabetes Rev. 7: 35-40.
30. Ma Y, Yu WD, Su B, Seshadri M, Luo W, et al. (2013) Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α,25-dihydroxycholecalciferol. Cancer 119: 563-574.
31. Barbosa EM, Nonogaki S, Katayama ML, Folgueira MA, Alves VF, et al. (2004) Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture. Virchows Arch 444: 175-182.
32. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, et al. (1996) Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11: 1003-1011.
33. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, et al. (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 14: 931-938.
34. Comper WD, (2009) Is the LPS-mediated proteinuria mouse model relevant to human kidney disease? Nat Med 15: 133.
35. Mundel P, Reiser J, Kriz W, (1997) Induction of differentiation in cultured rat and human podocytes. J Am Soc Nephrol 8: 697-705.
36. Sever S, Altintas MM, Nankoe SR, Möller CC, Ko D, et al. (2007) Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest 117: 2095-2104.
37. Arenas J, (2012) The role of bacterial lipopolysaccharides as immune modulator in vaccine and drug development. Endocr Metab Immune Disord Drug Targets12: 221-235.
38. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, et al. (2005) Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 18: 779-790.
39. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, et al. (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int 77: 1000-1009.
40. Wang W, Wang Y, Long J, Wang J, Haudek SB, et al. (2012) Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. Cell Metab. 15: 186-200.